Work

Secretogranin 2 binds LILRB4 resulting in immunosuppression

Year: 2025

Type: article

Source: Nature Immunology

DOI: 10.1038/s41590-025-02233-4

Institutions: The University of Texas Southwestern Medical Center, Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases, The University of Texas Health Science Center at Houston, Harold C. Simmons Comprehensive Cancer Center

Language: English

Topic: Immune cells in cancer

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: U.S. Department of Health and Human Services, Welch Foundation, Cancer Prevention and Research Institute of Texas, National Institutes of Health, National Cancer Institute, National Institute of General Medical Sciences

Awards: G1231444129, G1241018968, G147017651, Targeting immunosuppressive myeloid cells in tumor microenvironment, G3542525613, G3762527287, G4779534326, Advanced Cancer Antibody Drug Modalities Core Facility, ITIM-receptors for cancer treatment, Transmembrane signaling mechanisms of plexin, G5442619333, G6740541492, G8827492758, G9000179306, UT Southwestern Medical Center Simmons Comprehensive Cancer Center, Reprogramming myeloid cells to inhibit cancer development

OpenAlex ID: W4412640159

FWCI: 3.839

Cites: 65

Cited by: 13

Related to: 10